CYLD and neoplasm: As an initiating event, we then looked for a partner of SQSTM1, the K63 deubiquitinase CYLD, which is a tumor suppressor that constitutively regulates the NF-κB pathway by removing K63-linked ubiquitin chains from TRAF6 [10].